Lupin unveils Neuro-rehabilitation center in Mumbai

Mumbai: Pharma major, Lupin Limited, has announced the launch of a world-class Neuro-rehabilitation center, Atharv Ability in Bandra Kurla Complex (BKC), Mumbai, India.

"The first-of-its-kind robotic and computer-assisted, multi-disciplinary neuro-rehabilitation center is one of the most advanced rehabilitation centers in the country," the company stated.

Atharv Ability offers a range of rehabilitation programs for post-stroke patients, patients with traumatic brain injury, spinal cord injury, and pediatric neurological conditions as well as for other neurological conditions including Parkinsons, cerebral palsy and multiple sclerosis.

The neuro-rehabilitation center has a comprehensive suite of state-of-the-art equipment including an endeffector based robotic solution for gait and hand training, balance training and postural control, occupational therapy, speech therapy and swallowing therapy, cognitive behavioral therapy, aqua therapy, visual therapy, and virtual reality amongst others.

For the first time in India, Atharv Ability has introduced a dedicated home environment simulation space for “Activities of Daily Life” training that supports patient daily life and their interaction with the environment. The training improves their functionality and cognitive abilities and helps them integrate back into normal life.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “Neurological disorders and events lead to disability, creating an urgent need for multi-disciplinary centers with advanced therapeutic care delivered by neurological rehabilitation experts under one roof. This is why we have launched Atharv Ability, an innovative and futuristic neuro-rehabilitation center to improve health outcomes and quality of life of patients with neuro-disabilities through world-class patient-centric rehabilitation that is affordable and accessible for all.”

Read also: Lupin bags tentative USFDA nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets to control HIV infections